Vitrectomy Before Intravitreal Injection of AAV2/2 Vector Promotes Efficient Transduction of Retinal Ganglion Cells in Dogs and Nonhuman Primates
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (AAV) has emerged as a promising vector for retinal gene delivery to restore visual function in certain forms of inherited retinal dystrophies. Several studies in rodent models have shown that intravitreal injection of the AAV2/2 vector is the optimal route for efficient retinal ganglion cell (RGC) transduction. However, translation of these findings to larger species, including humans, is complicated by anatomical differences in the eye, a key difference being the comparatively smaller volume of the vitreous chamber in rodents. Here, we address the role of the vitreous body as a potential barrier to AAV2/2 diffusion and transduction in the RGCs of dogs and macaques, two of the most relevant preclinical models. We intravitreally administered the AAV2/2 vector carrying the CMV-eGFP reporter cassette in dog and macaque eyes, either directly into the vitreous chamber or after complete vitrectomy, a surgical procedure that removes the vitreous body. Our findings suggest that the vitreous body appears to trap the injected vector, thus impairing the diffusion and transduction of AAV2/2 to inner retinal neurons. We show that vitrectomy before intravitreal vector injection is an effective means of overcoming this physical barrier, improving the transduction of RGCs in dog and macaque retinas. These findings support the use of vitrectomy in clinical trials of intravitreal gene transfer techniques targeting inner retinal neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“44 We suggest that the lack of RGC transduction observed in the central retina may reflect a lack of specific receptors or the existence of physical barriers in the nonhuman primate retina that may not be present in rats and dogs.”
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Beltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
Intravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212 · cited 3×
“32 The differing levels of transduction in peripheral retina obtained in that study with respect to ours may be because of (1) the method of injection selected (we removed the vitreous body by vitrectomy before injection, whereas Yin et al. used the microplasmin enzyme to induce vitreoretinal…”
InfluentialPersistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160 · cited 2×
“21,22 23–29 Two studies have characterized RGC transduction in canine models after intravitreal injection of the AAV vector.”
Hellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142 · cited 1×
“The transduction of RGCs in rat retinas was consistent with previous data, 28 further supporting the rat as a valid and useful animal model in which to assess the ability of intravitreally administered AAV2/2 to effectively transduce inner retinal neurons.”
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108 · cited 3×
“30 In a study performed in the marmoset, a small New World primate, intravitreal injection of the AAV2/2 vector into the vitreous body resulted in transduction of RGCs in a limited region around the fovea and in the far-peripheral retina.”
InfluentialProvost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87
Self-citationDuisit, G., Conrath, H., Saleun, S., Folliot, S., Provost, N., Cosset, F.-L., Sandrin, V., Moullier, P., & Rolling, F. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0690 · Cited by 79
Self-citation
Cited by
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Gene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A. (2017) · Scientific Reports · doi:10.1038/srep45329 · Cited by 164
Vectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Metadata
- Authors
- Tshilenge, K.-T., Ameline, B., Weber, M., Mendes-Madeira, A., Nedellec, S., Biget, M., Provost, N., Libeau, L., Blouin, V., Deschamps, J.-Y., Le Meur, G., Colle, M.-A., Moullier, P., Pichard, V., & Rolling, F.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2016-06
- Volume
- 27
- Issue
- 3
- Pages
- 122-134
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2468157061
- Cited by
- 34
- References
- 14
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.